Actionable news
0
All posts from Actionable news
Actionable news in OMED: OncoMed Pharmaceuticals, Inc.,

OncoMed Announces Clinical Data to be Presented at the 2016 ASCO Annual Meeting

REDWOOD CITY, Calif., Apr 21, 2016 (GLOBE NEWSWIRE via COMTEX) --

OncoMed Pharmaceuticals Inc. OMED, +10.22% announced today it will present data from several clinical programs at the upcoming American Society of Clinical Oncology (ASCO) 2016 Annual Meeting being held June 3-7, 2016 in Chicago, IL.

Presentations include the first clinical data of OncoMed's Wnt pathway inhibitors (vantictumab and ipafricept) in combination therapy. The Phase 1b vantictumab (anti-Fzd7, OMP-18R5) clinical trial is in combination with paclitaxel in breast cancer and the Phase 1b ipafricept (FZD8-Fc, OMP-54F28) clinical trial is in combination therapy with carboplatin and paclitaxel in ovarian cancer.

In addition, updated survival data from OncoMed's Phase 1b clinical trials of demcizumab (OMP-21M18, anti-DLL4) in non-small cell lung cancer (NSCLC) and of tarextumab (anti-Notch2/3, OMP-59R5) in small cell lung cancer will be presented.

A complete list of OncoMed's accepted abstracts is provided below.

Poster Discussions

Saturday, June 4, 3:00pm - 4:15pm CT at E354b

1. Abstract #9023: A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM), Pemetrexed (PEM) & Carboplatin (CARBO) in Patients (pts) with 1st...


More